Chronic HCV infections: A model disease for therapy, economics and social-medical aspects;Chronische HCV-infektion: Modellerkrankung für therapie, ökonomie und sozialmedizinische aspekte

Gesundheitswesen

Volumn 69, Issue 3, 2007, Pages 146-150

  Rossol, S ^a  

^a KRANKENHAUS NORDWEST   (Germany)

Author keywords

Diagnosis; Epidemiology; Health economics; Hepatitis C infection; Natural course; Treatment

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; UNCLASSIFIED DRUG;

ARTICLE; DIAGNOSTIC PROCEDURE; HEALTH CARE SYSTEM; HEPATITIS C; HUMAN; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MONOTHERAPY; MORBIDITY; MORTALITY; QUALITY OF LIFE; RISK FACTOR; SOCIAL MEDICINE; TREATMENT OUTCOME; CHRONIC DISEASE; COST OF ILLNESS; DECISION SUPPORT SYSTEM; ECONOMICS; EPIDEMIC; GERMANY; HEALTH CARE DELIVERY; REVIEW; STATISTICAL MODEL; STATISTICS;

CHRONIC DISEASE; COST OF ILLNESS; DECISION SUPPORT SYSTEMS, CLINICAL; DELIVERY OF HEALTH CARE; DISEASE OUTBREAKS; GERMANY; HEPATITIS C, CHRONIC; HUMANS; MODELS, ECONOMIC; SOCIAL MEDICINE;

EID: 34248228069     PISSN: 09413790     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-971069     Document Type: Article

References (12)

1. Joseph F, Perz JF, Alter MJ: The coming wave of HCV-related liver disease: Dilemmas and challenges. Journal of Hepatology 2006; 44: 441-443
2. Robert Koch Institut. Epidemiologisches. Bulletin 2004, 10, Nr. 37.
3. Shepard SW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases 2005; 5: 558-567
4. DGVS Leitlinien zu Diagnostik, Verlauf und Therapie der Hepatitis-B und Hepatitis-C-Vitusinfektion. Zeitschrift für Gastroenterologie 2004; 42: 677-731
5. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A: Prevalence of Liver Disease in a Population of Asymptomatic Persons with Hepatitis C Virus Infection. Annual Internal Medicine 2002; 137: 961-964
6. Irving WL, Smith S, Cater R, Pugh S, Neal KR, Coupland CAC, Ryder SD, Thomson BJ, Pringle M, Bicknell M, Hippisley-Cox J: Clinical pathways for patients with newly diagnosed hepatitis C - What actually happens. Journal of Viral Hepatitis 2006; 13: 264-271
7. Rossol S, Bartel J: Schließen Sie Hepatitis B und C aus. MMW-Fortschr. Med. 2006; 48: 36-37
8. Pawlotsky JM: Therapy of Hepatitis C: From Empiricism to Eradication. Hepatology 2006; 43: 207-220
9. Siebert U, Sroczynski G, Wasem J, Greiner W, Ravens-Sieberer U, Aidelsburger P, Kurth B M, Bullinger M, Graf von der Schulenburg JM, Wong JB, Rossol S: Using Competence Network Collaboration and Decision-Analytic Modelling to Assess the Cost-Effectiveness of Interferon a-2b plus Ribavirin as Initial Treatment of Chronic Hepatitis C in Germany. European Journal of Health Economics 2005; 6: 112-123
10. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kuth BM, Manns MP, McHutchison JG, Wong JB: Cost-effectiveness of Peginterferonalpha-2b plus Ribavirin versus Interferon-alfa-2b for Initial Treatment of Chronic Hepatitis C. GUT 2003; 52: 425-432
11. Rossol S: Health economics and hepatology. Is treatment of chronic viral hepatitis cost effective? Deutsche Medizinische Wochenschrift 2005; 130: 231-233
12. Wasem J, Sroczynski G, Aidelsburger P, Buchberger B, Hessel F, Conrads-Frank A, Peters-Blochinger A, Kurth BM, Wong JB, Rossol S, Siebert U: Health economics of chronic infectious diseases: the example of hepatitis C. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2006; 49: 57-63